Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Hormonal Contraceptive Market

ID: MRFR/HC/41097-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026

Hormonal Contraceptive Market Research Report: Size, Share, Trend Analysis By Types (Pills, Injections, Implants, Patches, IUDs), By Administration Route (Oral, Parenteral, Transdermal, Intrauterine, Subcutaneous), By End Users (Pharmacies, Hospitals, Online Pharmacies, Clinics), By Formulation Type (Combination Hormonal Contraceptives, Progestin-Only Contraceptives, Extended Cycle Contraceptives) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Hormonal Contraceptive Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Pills | |
      2. 4.1.2 Injections | |
      3. 4.1.3 Implants | |
      4. 4.1.4 Patches | |
      5. 4.1.5 IUDs |
    2. 4.2 Healthcare, BY Administration Route (USD Billion) | |
      1. 4.2.1 Oral | |
      2. 4.2.2 Parenteral | |
      3. 4.2.3 Transdermal | |
      4. 4.2.4 Intrauterine | |
      5. 4.2.5 Subcutaneous |
    3. 4.3 Healthcare, BY End User (USD Billion) | |
      1. 4.3.1 Pharmacies | |
      2. 4.3.2 Hospitals | |
      3. 4.3.3 Online Pharmacies | |
      4. 4.3.4 Clinics |
    4. 4.4 Healthcare, BY Formulation Type (USD Billion) | |
      1. 4.4.1 Combination Hormonal Contraceptives | |
      2. 4.4.2 Progestin-Only Contraceptives | |
      3. 4.4.3 Extended Cycle Contraceptives |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Bayer AG (DE) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Pfizer Inc (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb Company (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Merck & Co., Inc. (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Teva Pharmaceutical Industries Ltd. (IL) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 HRA Pharma (FR) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Mylan N.V. (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Amgen Inc. (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Gedeon Richter Plc (HU) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    8. 6.5 US MARKET ANALYSIS BY END USER |
    9. 6.6 US MARKET ANALYSIS BY FORMULATION TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    12. 6.9 CANADA MARKET ANALYSIS BY END USER |
    13. 6.10 CANADA MARKET ANALYSIS BY FORMULATION TYPE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
    18. 6.15 GERMANY MARKET ANALYSIS BY FORMULATION TYPE |
    19. 6.16 UK MARKET ANALYSIS BY TYPE |
    20. 6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    21. 6.18 UK MARKET ANALYSIS BY END USER |
    22. 6.19 UK MARKET ANALYSIS BY FORMULATION TYPE |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
    26. 6.23 FRANCE MARKET ANALYSIS BY FORMULATION TYPE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
    30. 6.27 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    33. 6.30 ITALY MARKET ANALYSIS BY END USER |
    34. 6.31 ITALY MARKET ANALYSIS BY FORMULATION TYPE |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
    38. 6.35 SPAIN MARKET ANALYSIS BY FORMULATION TYPE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    46. 6.43 CHINA MARKET ANALYSIS BY END USER |
    47. 6.44 CHINA MARKET ANALYSIS BY FORMULATION TYPE |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    50. 6.47 INDIA MARKET ANALYSIS BY END USER |
    51. 6.48 INDIA MARKET ANALYSIS BY FORMULATION TYPE |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
    55. 6.52 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
    67. 6.64 THAILAND MARKET ANALYSIS BY FORMULATION TYPE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
    71. 6.68 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
    80. 6.77 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
    84. 6.81 MEXICO MARKET ANALYSIS BY FORMULATION TYPE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY FORMULATION TYPE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Pills
  • Injections
  • Implants
  • Patches
  • IUDs

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Oral
  • Parenteral
  • Transdermal
  • Intrauterine
  • Subcutaneous

Healthcare By End User (USD Billion, 2025-2035)

  • Pharmacies
  • Hospitals
  • Online Pharmacies
  • Clinics

Healthcare By Formulation Type (USD Billion, 2025-2035)

  • Combination Hormonal Contraceptives
  • Progestin-Only Contraceptives
  • Extended Cycle Contraceptives

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions